Efficacy of ECT in Chronic, Severe, Antidepressant- and CBT-Refractory PTSD: An Open, Prospective Study

Brain Stimulation

Volumn 3, Issue 1, 2010, Pages 28-35

  Margoob, Mushtaq A ^a   Ali, Zaffar ^b   Andrade, Chittaranjan ^c  

^a GOVERNMENT MEDICAL COLLEGE   (India)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

CBT refractory; depression; electroconvulsive therapy; medication refractory; posttraumatic stress disorder

Indexed keywords

ANTIDEPRESSANT AGENT; MIRTAZAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; ELECTROCONVULSIVE THERAPY; FEMALE; FOLLOW UP; HUMAN; MALE; OUTCOME ASSESSMENT; OUTPATIENT CARE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RATING SCALE; REMISSION; SCORING SYSTEM; TREATMENT OUTCOME; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT FAILURE; YOUNG ADULT;

ADULT; ANTIDEPRESSIVE AGENTS; COGNITIVE THERAPY; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 75149113481     PISSN: 1935861X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brs.2009.04.005     Document Type: Article

References (45)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed (1994), American Psychiatric Association, Washington, DC
2. Hamner M.B., Robert S., and Frueh B.C. Treatment-resistant posttraumatic stress disorder: strategies for intervention. CNS Spectr 9 (2004) 740-752
3. Schoenfeld F.B., Marmar C.R., and Neylan T.C. Current concepts in pharmacotherapy for posttraumatic stress disorder. Psychiatr Serv 55 (2004) 519-531
4. Ipser J., Seedat S., and Stein D.J. Pharmacotherapy for post-traumatic stress disorder - a systematic review and meta-analysis. S Afr Med J 96 (2006) 1088-1096
5. Zhang W., and Davidson J.R. Post-traumatic stress disorder: an evaluation of existing pharmacotherapies and new strategies. Expert Opin Pharmacother 8 (2007) 1861-1870
6. Brady K.T., Killeen T.K., Brewerton T., and Lucerini S. Comorbidity of psychiatric disorders and posttraumatic stress disorder. J Clin Psychiatry 61 Suppl 7 (2000) 22-32
7. American Psychiatric Association. The Practice of ECT: Recommendations for Practice, Training, and Privileging. Task Force Report on ECT (2001), American Psychiatric Press, Washington, DC
8. Ursano R.J., Bell C., Eth S., Friedman M., Norwood A., Pfefferbaum B., et al., Work Group on ASD and PTSD; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Am J Psychiatry 161 11 Suppl (2004) 3-31
9. Helsley S., Sheikh T., Kim K.Y., and Park S.K. ECT Therapy in PTSD. Am J Psychiatry 156 (1999) 494-495
10. Hanretta A.T., and Malek-Ahmadi P. Combined use of ECT with duloxetine and olanzapine: a case report. J ECT 22 (2006) 139-141
11. Watts B.V. Electroconvulsive therapy for comorbid major depressive disorder and posttraumatic stress disorder. J ECT 23 (2007) 93-95
12. Hollander E., and Simeon D. Anxiety Disorders. In: Hales R.E., and Yudofsky S.G. (Eds). Textbook of Clinical Psychiatry. 4th ed (2003), American Psychiatric Publishing, Inc, Washington, DC 543-630
13. Post R.M., Weiss S.R., Smith M., Li H., and McCann U. Kindling versus quenching: implications for the evolution and treatment of posttraumatic stress disorder. Ann N Y Acad Sci 821 (1997) 285-295
14. Sackeim H.A. The anticonvulsant hypothesis of the mechanisms of action of ECT: current status. J ECT 15 (1999) 5-26
15. de Kloet C.S., Vermetten E., Geuze E., Kavelaars A., Heijnen C.J., and Westenberg H.G. Assessment of HPA-axis function in posttraumatic stress disorder: pharmacological and non-pharmacological challenge tests, a review. J Psychiatr Res 40 (2006) 550-567
16. Fink M. Electroshock: Restoring the Mind (1999), Oxford University Press, New York
17. Sapolsky R.M. Why stress is bad for your brain. Science 273 (1996) 749-750
18. Madsen T.M., Treschow A., Bengzon J., Bolwig T.G., Lindvall O., and Tingstrom A. Increased neurogenesis in a model of electroconvulsive therapy. Biol Psychiatry 47 (2000) 1043-1049
19. Scott B.W., Wojtowicz J.M., and Burnham W.M. Neurogenesis in the dentate gyrus of the rat following electroconvulsive shock seizures. Exp Neurol 165 (2000) 231-236
20. Hellsten J., Wennstrom M., Mohapel P., Ekdahl C.T., Bengzon J., and Tingstrom A. Electroconvulsive seizures increase hippocampal neurogenesis after chronic corticosterone treatment. Eur J Neurosci 16 (2002) 283-290
21. Hellsten J., West M.J., Arvidsson A., Ekstrand J., Jansson L., Wennstrom M., et al. Electroconvulsive seizures induce angiogenesis in adult rat hippocampus. Biol Psychiatry 58 (2005) 871-878
22. Wennstrom M., Hellsten J., Ekstrand J., Lindgren H., and Tingstrvm A. Corticosterone-induced inhibition of gliogenesis in rat hippocampus is counteracted by electroconvulsive seizures. Biol Psychiatry 59 (2006) 178-186
23. Blake D.D., Weathers F.W., Nagy L.M., Kaloupek D.G., Klauminzer G., Charney D.S., et al. A clinician rating scale for assessing current and lifetime PTSD: the CAPS-1. Behav Ther 13 (1990) 187-188
24. Blake D.D., Weathers F.W., Nagy L.M., Kaloupek D.G., Gusman F.D., Charney D.S., et al. The development of a Clinician-Administered PTSD Scale. J Trauma Stress 8 (1995) 75-90
25. Brady K., Pearlstein T., Asnis G.M., Baker D., Rothbaum B., Sikes C.R., et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 283 (2000) 1837-1844
26. Davidson J.R., Rothbaum B.O., van der Kolk B.A., Sikes C.R., and Farfel G.M. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 58 (2001) 485-492
27. Tucker P., Zaninelli R., Yehuda R., Ruggiero L., Dillingham K., and Pitts C.D. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 62 (2001) 860-868
28. Davidson J., Rothbaum B.O., Tucker P., Asnis G., Benattia I., and Musgnung J.J. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol 26 (2006) 259-267 Erratum in: J Clin Psychopharmacol. 2006;26:473
29. Davidson J., Baldwin D., Stein D.J., Kuper E., Benattia I., Ahmed S., et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry 63 (2006) 1158-1165
30. Montgomery S.A., and Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 134 (1979) 382-389
31. Guy W. Assessment Manual for Psychopharmacology, Revised. US Dept of Health, Education, and Welfare Publication (ADM) 76-368 (1976), National Institute of Mental Health, Rockville, MD 218-222
32. Weathers F.W., Keane T.M., and Davidson J.R. Clinician-administered PTSD scale: a review of the first ten years of research. Depress Anxiety 13 (2001) 132-156
33. Tucker P., Trautman R.P., Wyatt D.B., Thompson J., Wu S.-C., Capece J.A., et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68 (2007) 201-206
34. Margoob M.A., and Ahmad S.A. Community prevalence of adult posttraumatic stress disorder in South Asia: experience from Kashmir. JK-Practitioner 13 Suppl 1 (2006) S18-S25
35. Ali Z, Margoob MA, Dar MM, Hussain A. First report of PTSD in disturbed Kashmir: characteristics of a treatment-seeking sample. Poster presented at the 17th Annual Meetingof the International Society for Traumatic Stress Studies, New Orleans, Louisiana, USA, 2001.
36. Marshall R.D., Beebe K.L., Oldham M., and Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 158 (2001) 1982-1988
37. Zohar J., Amital D., Miodownik C., Kotler M., Bleich A., Lane R.M., et al. Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J Clin Psychopharmacol 22 (2002) 190-195
38. Friedman M.J., Marmar C.R., Baker D.G., Sikes C.R., and Farfel G.M. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry 68 (2007) 711-720
39. Simon N.M., Connor K.M., Lang A.J., Rauch S., Krulewicz S., LeBeau R.T., et al. Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. J Clin Psychiatry 69 (2008) 400-405
40. Hamner M.B. Psychotic features and combat associated PTSD. Depress Anxiety 5 (1997) 34-38
41. Hamner M.B., Frueh B.C., Ulmer H.G., and Arana G.W. Psychotic features and illness severity in combat veterans with chronic posttraumatic stress disorder. Biol Psychiatry 45 (1999) 846-852
42. David D., Kutcher G.S., Jackson E.I., and Mellman T.A. Psychotic symptoms in combat-related posttraumatic stress disorder. Journal of Clinical Psychiatry 60 (1999) 29-32
43. Lindley S.E., Carlson E., and Sheikh J. Psychotic symptoms in posttraumatic stress disorder. CNS Spectr 5 (2000) 52-57
44. Kendell R.E. The present status of electroconvulsive therapy. Br J Psychiatry 139 (1981) 265-283
45. Andrade C. Quantifying the ECT dose: the right unit remains elusive. J ECT 17 (2001) 75